Skip to content

Opus Genetics IRD Expired (in dollars per share)

Expired (in dollars per share) at other companies

HTF
Heartflow, Inc. Common StockHTFL
854%
Nabors Industries logo
Nabors IndustriesNBR
$537.45-40.1%
Healthcare Services Group logo
Healthcare Services GroupHCSG
$34.21+9.8%
Frequency Electronics logo
Frequency ElectronicsFEIM
$13.24+38.5%
TFS Financial logo
TFS FinancialTFSL
$14.87-0.2%
LivaNova logo
LivaNovaLIVN
$79.49+3.6%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodExercisePricePerWarrant.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's expired (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's expired (in dollars per share)?
Opus Genetics (IRD) reported expired (in dollars per share) of $0.00 in Q1 2026.
What does expired (in dollars per share) mean?
The exercise price per share for equity instruments that reached their expiration date without being exercised during the period. This represents the value at which these instruments were originally set to convert, now rendered void. It provides context on the historical valuation expectations of the company's equity-linked securities.